How insurers are powerless to control the cost of a "me-too" cancer drug

And thus another example of letting health costs run rampant:

The rise in cancer-drug prices is a microcosm of broader trends pushing up health care costs nationally. Despite decades of efforts by governments and insurers to restrain costs, patients continue to want the newest “” and most expensive “” drugs and medical devices. And doctors and the health care industry have little reason to keep costs in check, because insurers rarely deny coverage for new treatments on the basis of price.

Prev
Next